Nanobodies as probes to investigate purinergic signaling

Biochem Pharmacol. 2021 May:187:114394. doi: 10.1016/j.bcp.2020.114394. Epub 2021 Jan 1.

Abstract

Nanobodies (VHHs) are the single variable immunoglobulin domains of heavy chain antibodies (hcAbs) that naturally occur in alpacas and other camelids. The two variable domains of conventional antibodies typically interact via a hydrophobic interface. In contrast, the corresponding surface area of nanobodies is hydrophilic, rendering these single immunoglobulin domains highly soluble, robust to harsh environments, and exceptionally easy to format into bispecific reagents. In homage to Geoffrey Burnstock, the pioneer of purinergic signaling, we provide a brief history of nanobody-mediated modulation of purinergic signaling, using our nanobodies targeting P2X7 and the NAD+-metabolizing ecto-enzymes CD38 and ARTC2.2 as examples.

Keywords: ADP-ribosylation; Nanobodies; Purinergic signaling.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antisense Elements (Genetics) / administration & dosage
  • Antisense Elements (Genetics) / genetics
  • Antisense Elements (Genetics) / metabolism*
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Immunoglobulin Heavy Chains / metabolism
  • Protein Structure, Tertiary
  • Purinergic Agonists / administration & dosage
  • Purinergic Antagonists / administration & dosage
  • Receptors, Purinergic / genetics
  • Receptors, Purinergic / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Single-Domain Antibodies / administration & dosage
  • Single-Domain Antibodies / genetics
  • Single-Domain Antibodies / metabolism*

Substances

  • Antisense Elements (Genetics)
  • Immunoglobulin Heavy Chains
  • Purinergic Agonists
  • Purinergic Antagonists
  • Receptors, Purinergic
  • Single-Domain Antibodies